RT Journal Article
SR Electronic
T1 Parkinson’s disease causality and heterogeneity: a proteogenomic view
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.09.22272131
DO 10.1101/2022.03.09.22272131
A1 Sergio Kaiser
A1 Luqing Zhang
A1 Brit Mollenhauer
A1 Jaison Jacob
A1 Simonne Longerich
A1 Jorge Del-Aguila
A1 Jacob Marcus
A1 Neha Raghavan
A1 David Stone
A1 Olumide Fagboyegun
A1 Douglas Galasko
A1 Mohammed Dakna
A1 Bilada Bilican
A1 Mary Dovlatyan
A1 Anna Kostikova
A1 Jingyao Li
A1 Brant Peterson
A1 Michael Rotte
A1 Vinicius Sanz
A1 Tatiana Foroud
A1 Karla Gonzalez
A1 Samantha J. Hutten
A1 Mark Frasier
A1 Hirotaka Iwaki
A1 Andrew Singleton
A1 Ken Marek
A1 Karen Crawford
A1 Fiona Elwood
A1 Mirko Messa
A1 Pablo Serrano-Fernandez
YR 2022
UL http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272131.abstract
AB Pathogenesis and clinical heterogeneity in Parkinson’s disease (PD) have been evaluated from genetic, pathological, and clinical perspective. Technology allowing for high-throughput proteomic analyses in cerebrospinal fluid (CSF) has opened new opportunities to scrutinize this heterogeneity. This is to date the most comprehensive proteomics profiling in CSF of PD patients and controls, both in terms of subjects (n=1103) and proteins (n=4135).Combining CSF aptamer-based proteomics with genetics across all samples we determined the protein quantitative trait loci (pQTLs) linking genetic variants with protein abundance in CSF. Analyzing pQTLs together with summary statistics from the largest PD genome wide association study (GWAS) led us to identify 68 potential causal proteins by Mendelian randomization. The top PD causal protein, GPNMB, has colocalization support and has been reported to be upregulated in the substantia nigra of PD patients.We also examined three subcohorts of PD patients: LRRK2 variant carriers (LRRK2+), GBA variant carriers (GBA+) and idiopathic PD patients, each with their respective controls. The second goal was to identify proteomic differences between PD patients and controls within and between the three subcohorts. Statistical analyses revealed six proteins differentially expressed when comparing GBA+ PD patients with unaffected GBA+ controls, seven proteins when comparing LRRK2+ PD patients with unaffected LRRK2+ controls and 23 proteins when comparing idiopathic PD patients with healthy controls who did not carry any severe PD mutations.Furthermore a hypothesis-free stratification of idiopathic PD patients based on their proteomic profile revealed two protein modules based on the co-expression network structure. Based on these modules, cluster analysis revealed two patient endotypes for idiopathic PD.Differences in the CSF proteomic signature between subcohorts and between idiopathic endotypes, as well as causal targets identified using both proteomics and genetics may together influence the way we approach the identification of potential therapeutic targets in PD.Competing Interest StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck. Protein measurements were performed at SomaLogic. A.K., B.B., B.P. F.E., J.J., J.L., L.Z., M. Dovlatyan, M.M., M.R., P.S-F., S.K. and V.S. are or have been employees of Novartis; J.J., S.K., M.M. are also stockholders of Novartis. D.S., J.D-A., J.M., N.R. and S.L. are or have been employees of Merck. All other authors have no conflict of interests to declare.Funding StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples we have used for the study are available in the PPMI repositoryI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results of the current study are publicly available on the LONI database and all data produced in the present work are contained in the manuscript